The cancer diagnostics technology developer raised $300m from investors also including Kaiser Permanente, Intermountain, Novartis and Roche, but its machine learning model points to where GV is increasingly active.

Internet and technology group Alphabet’s GV subsidiary took part in a $300m series D round for US-based cancer detection technology developer Freenome on Tuesday, further expanding a thriving life sciences portfolio.

Perceptive Advisors and RA Capital Management co-led the round, which included care providers Kaiser Permanente and Intermountain Healthcare (through Intermountain Ventures), pharmaceutical firms Novartis and Roche – the latter through its Roche Venture Fund – and investment and financial services group Fidelity.

Andreessen Horowitz’s Life Sciences Growth Fund, the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn